Consolidated Balance Sheets - USD ($) $ in Millions		Dec. 31, 2024	Dec. 31, 2023
Assets
Cash and cash equivalents		$ 7,550	$ 7,822
Investments		665	925
Accounts receivable, net		24,227	17,722
Inventories		6,692	5,645
Other current assets		2,732	2,169
Assets of businesses held for sale		7,004	3,068
Total current assets		48,870	37,351
Long-term investments		15,128	17,985
Reinsurance recoverables		4,378	4,835
Property and equipment		3,654	3,695
Goodwill		44,370	44,259
Other intangible assets		29,417	30,863
Other assets		2,786	3,421
Separate account assets		7,278	7,430
Assets of businesses held for sale, non-current		0	2,922
TOTAL ASSETS		155,881	152,761
Liabilities
Current insurance and contractholder liabilities		5,388	5,514
Pharmacy and other service costs payable		28,465	19,815
Accounts payable		9,294	8,553
Accrued expenses and other liabilities		9,387	9,955
Short-term debt		3,035	2,775
Liabilities of businesses held for sale		2,410	2,104
Total current liabilities		57,979	48,716
Non-current insurance and contractholder liabilities		10,254	10,904
Deferred tax liabilities, net		6,975	7,173
Other non-current liabilities		3,215	3,441
Long-term debt		28,937	28,155
Separate account liabilities		7,278	7,430
Liabilities of businesses held for sale, non-current		0	591
TOTAL LIABILITIES		114,638	106,410
Contingencies — Note 21
Redeemable noncontrolling interests		0	107
Shareholders' equity
Common stock	[1]	4	4
Additional paid-in capital		31,288	30,669
Accumulated other comprehensive loss		(2,341)	(1,864)
Retained earnings		43,519	41,652
Less: Treasury stock, at cost		(31,437)	(24,238)
TOTAL SHAREHOLDERS' EQUITY		41,033	46,223
Other noncontrolling interests		210	21
Total equity		41,243	46,244
Total liabilities and equity		$ 155,881	$ 152,761

[1] Par value per share, $0.01; shares issued, 403 million as of December 31, 2024 and 400 million as of December 31, 2023; authorized shares, 600 million.